Showing 2,392 news articles about HIV treatment

Filters Content type: Editors' picks Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

New & experimental HIV treatments

Merck pauses 'very important' HIV program after seeing red flag in phase 2 trial of once-weekly combo

Editor's pick
FierceBiotech
22 November 2021
New & experimental HIV treatments

Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1

Editor's pick
Merck press release
19 November 2021
Injectable & long-acting HIV treatment

England & Wales: NICE approves first long-acting injectable HIV-1 treatment

Editor's pick
National Institute for Health and Care Excellence
18 November 2021
Treatment simplification strategies

Implications of historical M184V on use of dual dolutegravir/lamivudine ART

Editor's pick
i-Base
15 November 2021
Access to healthcare

Uganda: Shortage of raltegravir worries patients on third line HIV treatment

Editor's pick
The Independent
15 November 2021
Injectable & long-acting HIV treatment

Cabenuva Works Well Regardless of Body Weight

Editor's pick
POZ
5 November 2021
Treatment for women

It’s 2021. Where Are the Women in HIV Clinical Trials?

Editor's pick
TheBodyPro
31 October 2021
PrEP science

Kidney Toxicity Rare With Daily or On-Demand (As-Needed) PrEP

Editor's pick
NATAP
31 October 2021
New & experimental HIV treatments

Merck's HIV program closer to regulator's doorstep with two phase 3 trials showing efficacy comparable to existing meds

Editor's pick
FierceBiotech
31 October 2021
HIV treatment for children & young people

WHO Updates Pediatric Dosing Tool for Antiretroviral Medicines

Editor's pick
Medscape (requires free registration)
31 October 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV

Editor's pick
ViiV Healthcare
28 October 2021
Low & theoretical transmission risks

Fact Check - Transmission of HIV by needle injuries is highly unlikely, according to a British AIDS charity

Editor's pick
Reuters
27 October 2021
Bad science & bogus treatments

Facebook, YouTube Take Down Bolsonaro Video That Said Vaccines Cause AIDS

Editor's pick
The Wire
26 October 2021
Injectable & long-acting HIV treatment

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

Editor's pick
Gilead press release
26 October 2021
Sexually transmitted infections epidemiology

Should we be worried about donovanosis, a rare, so-called 'flesh-eating' STI?

Editor's pick
The Washington Post
26 October 2021
New & experimental HIV treatments

Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection

Editor's pick
Merck press release
25 October 2021
Injectable & long-acting HIV treatment

Cabotegravir (Vocabria®) is accepted for use within NHSScotland

Editor's pick
Scottish Medicines Consortium
11 October 2021
Treatment outcomes & life expectancy

US: Black Women With HIV Die Earlier Than Their White Female or Black Male Peers

Editor's pick
POZ
11 October 2021
PrEP science

Islatravir Subdermal Implant for HIV PrEP Has Promising Phase 1 Trial

Editor's pick
Contagion Live
7 October 2021
People & personal stories

Fit at 50: gaining weight at midlife isn’t inevitable

Editor's pick
POZ
4 October 2021
Treatment outcomes & life expectancy

US: Among people with HIV, Black women have highest rate of premature death

Editor's pick
Healio
4 October 2021
Injectable & long-acting HIV treatment

Shionogi licenses out 3rd-gen HIV asset to ViiV

Editor's pick
FierceBiotech
28 September 2021
Drug interactions & pharmacokinetics

No Drop in Rate of Drug-Drug & Interactions With HIV Drugs Since 1985

Editor's pick
NATAP
27 September 2021
Bad science & bogus treatments

AIDS Misinformation and Failed Policies in Georgia

Editor's pick
TheBody
27 September 2021